NAMS NewAmsterdam Pharma Company N.V.

NASDAQ
$26.98

NewAmsterdam Pharma Company N.V. (NAMS) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.50 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.3% since its last earnings release on August 5, 2026.

NewAmsterdam Pharma Company N.V. Missed Consensus Estimates
Wednesday, August 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.50)
Rev est $13.95M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $27.51

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Holding B.V. is a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases. NewAmsterdam Pharma Holding B.V., formerly known as Frazier Lifesciences Acquisition Corporation, is based in MENLO PARK, Calif.

Sector

Healthcare

Industry

Drug Manufacturers/Other